Elborn J S, Shale D J, Britton J R
Section of Respiratory Medicine, University of Wales College of Medicine, Llandough Hospital, Penarth, U.K.
Respir Med. 1994 Feb;88(2):135-8. doi: 10.1016/0954-6111(94)90026-4.
Heart-lung transplantation has become an established treatment for end stage respiratory failure secondary to cystic fibrosis. The success of this form of treatment, and the increasing survival of such patients, suggests there will be an increased need for transplantation over the next decade. We have used cystic fibrosis population predictions and all cause mortality data to estimate the number of cardio-pulmonary deaths, due to cystic fibrosis, over the next decade and to estimate the number of such patients who are likely to benefit from heart-lung transplantation. We estimate that there will be between 85 and 127 potential transplant recipients with cystic fibrosis each year over the next decade. During 1990, 1991 and 1992 there were less than 40 transplants each year in such patients. These data emphasize the need to expand transplantation services and to maintain the availability of donor organs.
心肺移植已成为治疗囊性纤维化继发终末期呼吸衰竭的既定疗法。这种治疗方式的成功以及此类患者存活率的不断提高,表明在未来十年对移植的需求将会增加。我们利用囊性纤维化人群预测数据和全因死亡率数据,来估算未来十年因囊性纤维化导致的心肺死亡人数,并估算可能从心肺移植中受益的此类患者人数。我们估计,在未来十年中,每年将有85至127名患有囊性纤维化的潜在移植受者。在1990年、1991年和1992年,此类患者每年接受的移植手术少于40例。这些数据凸显了扩大移植服务以及维持供体器官供应的必要性。